Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio Inc. is experiencing notable growth, with OviTex unit sales increasing by 20% for the quarter, supported by new customer acquisitions and the successful launch of larger-sized OviTex PRS products. The company reported a gross margin of 65.9%, reflecting an improvement of 230 basis points, which indicates healthy profitability amid ongoing investments in its product portfolio and sales force. Additionally, TELA's financial position has been strengthened by recent equity raises and expanded debt capacity, providing a solid cash runway that may enable continued expansion and innovation through 2026 and beyond.

Bears say

TELA Bio has lowered its full-year 2025 revenue guidance to at least 16% growth year-over-year, a significant decrease from the previously projected growth of 23-27%, now implying revenue of at least $80.4 million compared to earlier expectations. Furthermore, the company's growth outlook for fiscal year 2026 has also been reduced from at least 15% to a mere 8%, reflecting ongoing challenges such as sales force dislocation, pressure on average selling prices, and the strategic focus on denser populated territories, potentially sidelining existing coverage areas. Additionally, TELA's recent quarterly sales of $20.9 million fell short of both internal and market consensus estimates, highlighting underlying weaknesses in sales volumes amid seasonal factors and operational adjustments.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.